Computed Tomography Study Assesses Model for Predicting Recurrence of Non-Small Cell Lung Cancer
A predictive model for non-small cell lung cancer (NSCLC) recurrence, based on clinical parameters and CT findings, demonstrated an 85.2 percent AUC and 83.3 percent sensitivity rate, according to external validation testing in a new study.
Can MRI-Based Deep Learning Improve Risk Stratification in PI-RADS 3 Cases?
In external validation testing, a deep learning model demonstrated an average AUC of 87.6 percent for detecting clinically significant prostate cancer (csPCA) on prostate MRI for patients with PI-RADS 3 assessments.
What Emerging CT Research Reveals About Obesity and Post-Op Survival for Non-Small Cell Lung Cancer
For those without low skeletal muscle mass on CT and myosteatosis, obese patients have a 23 percent lower risk of death than non-obese patients after undergoing curative resection for non-small cell lung cancer, according to newly published research.
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
In a recent interview, Joshua Gowin, M.D., discussed emerging brain MRI research that showed a significant association between heavy lifetime use of cannabis and reduced brain activity for working memory tasks in young adults.
Current and Emerging Legislative Priorities for Radiology in 2025
In a recent interview, Amy Patel, M.D., discussed key points of emphasis for legislative advocacy in radiology, including long-term reform in Medicare reimbursement, improved coverage of breast cancer screening and mitigation of the ongoing radiology workforce shortage.
Emerging PET Agent Garners Second FDA Fast Track Designation for Prostate Cancer Imaging
In addition to an August FDA fast track designation for PSMA PET imaging in patients with suspected metastasis, the radiopharmaceutical 64Cu-SAR-bisPSMA has earned another fast track designation for imaging of biochemical recurrence.
Study Examines Prognostic Value of Baseline PSMA PET/CT Factors in Patients with mCRPC
Doubling of total tumor volume on PSMA PET/CT is 41 percent more likely to reduce overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC), according to new research.